Century Therapeutics to Host Live Fireside Chat Focused on Newly Prioritized Preclinical Cell Therapy Programs for Autoimmune Diseases and Cancer on Tuesday, April 22, 2025

Rhea-AI Summary

Century Therapeutics (NASDAQ: IPSC) has announced a live fireside chat scheduled for Tuesday, April 22, 2025, at 10:00 a.m. EDT to discuss their prioritized preclinical cell therapy programs. The event will showcase three key investigational therapies:

• CNTY-308: A CD19-targeted CAR-iT cell therapy
• CNTY-341: A CD19/CD22 dual-targeted CAR-iT cell therapy
• A solid tumor CAR iT program focusing on Nectin-4 CAR and other validated targets

All programs utilize advanced iPSC-derived 'tunable' CD4+/CD8+ ab T cells and incorporate the company's proprietary Allo-Evasion™ 5.0 technology, designed for comprehensive immune evasion. The presentation will also explore the potential expansion of their selective iPSC differentiation expertise to non-immune effector cells. The event will be accessible through Century's website, with a replay available for at least 30 days.

PHILADELPHIA, April 15, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in autoimmune disease and cancer, today announced that company management will host a live fireside chat on Tuesday, April 22, 2025, at 10:00 a.m. EDT to discuss details and data for its prioritized preclinical cell therapy programs targeting autoimmune diseases and cancer.

The event will feature discussion of CNTY-308, a CD19-targeted CAR-iT investigational cell therapy, CNTY-341, a CD19/CD22 dual-targeted CAR-iT investigational cell therapy, and the company’s first solid tumor CAR iT investigational program exploiting Nectin-4 CAR and other validated targets. Each of these programs is anchored by advanced iPSC-derived ’tunable’ CD4+/CD8+ ab T cells. In addition, each of these programs is engineered with the company’s proprietary immune evasion technology, Allo-Evasion™ 5.0, which is designed to enable holistic evasion of T cell, NK cell, and humoral immunity. The discussion will also highlight the potential for the company’s expertise in selective iPSC differentiation to extend to non-immune effector cells.

The live event can be accessed on the Investors page of Century’s website at www.centurytx.com. A replay will be available on the company’s website shortly following the completion of the event and will be available for at least 30 days.

About Century Therapeutics
Century Therapeutics (NASDAQ: IPSC) is a clinical-stage biotechnology company leveraging its expertise in cellular reprogramming, genetic engineering, and manufacturing to develop cell therapies with the potential to provide meaningful advantages over existing cell therapies. Century’s genetically engineered, iPSC-derived cell therapy pipeline includes programs designed to address autoimmune diseases and cancers. Century believes its commitment to developing off-the-shelf cell therapies will expand patient access and provide an opportunity to advance the course of autoimmune disease and cancer care. For more information on Century Therapeutics, please visit www.centurytx.com and connect with us on LinkedIn.

Forward-Looking Statements
This press release and statements of our management made in connection therewith contain forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements regarding our clinical development plans and timelines are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “forecast,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this press release are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control, including, among others: our ability to successfully advance our current and future product candidates through development activities, preclinical studies, and clinical trials; our dependence on the success of our lead product candidate, CNTY-101; our ability to progress CNTY-101 through clinical development; our ability to meet development milestones on anticipated timelines; uncertainties inherent in the results of preliminary data, pre-clinical studies and earlier-stage clinical trials, which may not be predictive of final results or the results of later-stage clinical trials; our ability to obtain FDA clearance of our future IND submissions and commence and complete clinical trials on expected timelines, or at all; our reliance on the maintenance of certain key collaborative relationships for the manufacturing and development of our product candidates; the timing, scope and likelihood of regulatory filings and approvals, including final regulatory approval of our product candidates; the impact of geopolitical issues, banking instability and inflation on our business and operations, supply chain and labor force; the performance of third parties in connection with the development of our product candidates, including third parties conducting our clinical trials as well as third-party suppliers and manufacturers; our ability to successfully commercialize our product candidates and develop sales and marketing capabilities, if our product candidates are approved; our ability to recruit and maintain key members of management and our ability to maintain and successfully enforce adequate intellectual property protection. These and other risks and uncertainties are described more fully in the “Risk Factors” section of our most recent filings with the Securities and Exchange Commission and available at www.sec.gov. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

For More Information:

Century Therapeutics
Morgan Conn, PhD
Chief Financial Officer
investor.relations@centurytx.com

JPA Health
Sarah McCabe
smccabe@jpa.com

FAQ

What new cell therapy programs will Century Therapeutics (IPSC) discuss on April 22, 2025?

Century will discuss CNTY-308 (CD19-targeted), CNTY-341 (CD19/CD22 dual-targeted), and a solid tumor program focusing on Nectin-4 CAR therapies.

What is the Allo-Evasion™ 5.0 technology used in Century Therapeutics' (IPSC) cell therapies?

Allo-Evasion™ 5.0 is Century's proprietary technology designed to enable holistic evasion of T cell, NK cell, and humoral immunity in their cell therapies.

When and where can investors access Century Therapeutics' (IPSC) April 2025 fireside chat?

The fireside chat will be accessible on April 22, 2025, at 10:00 a.m. EDT through Century's website (www.centurytx.com), with a 30-day replay available.

What types of diseases are targeted by Century Therapeutics' (IPSC) new cell therapy programs?

The programs target both autoimmune diseases and cancer, including solid tumors, using iPSC-derived 'tunable' CD4+/CD8+ ab T cells.